Protein Summary
Lipid-modifying enzyme that acts as major regulator of adipocyte lipolysis by catalyzing the release of fatty acids from phospholipids in adipose tissue (PubMed:19615464, PubMed:19047760, PubMed:20837014, PubMed:22605381, PubMed:22923616). Shows phospholipase A1 and A2 activity, catalyzing the calcium-independent hydrolysis of acyl groups in various phosphatidylcholines (PC) and phosphatidylethanolamine (PE) (PubMed:19615464, PubMed:19047760, PubMed:20837014, PubMed:22605381, PubMed:22923616). For most substrates, phospholipase A1 activity is much higher than phospholipase A2 activity (PubMed:19047760). Phospholipase activity causes decreased intracellular levels of ether-type lipids, affecting peroxisome metabolism (By similarity). May also have acyltransferase activity: catalyzes both N-acylation of phosphatidylethanolamine to form N-acyl-phosphatidylethanolamine and O-acylation of lyso-phosphatidylcholines to form phosphatidylcholines (PubMed:22605381, PubMed:25383759). The relevanc ...more
- ENST00000323646
- ENSP00000320337
- ENSG00000176485
- ENST00000415826
- ENSP00000389124
- HRASLS3
- HREV107
- AdPLA
- HRSL3
- HRASLS3
- HREV107
- PLA2G16
- PLAAT-3
- H-REV107
- HREV107-1
- HREV107-3
- H-REV107-1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
disease perturbation | 0.93 | ||
transcription factor perturbation | 0.88 | ||
virus perturbation | 0.72 | ||
gene perturbation | 0.71 | ||
small molecule perturbation | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 58.9 (req: < 5)
Gene RIFs: 20 (req: <= 3)
Antibodies: 290 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 58.9 (req: >= 5)
Gene RIFs: 20 (req: > 3)
Antibodies: 290 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 20
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 16
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0